Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12613000845730
Ethics application status
Approved
Date submitted
12/05/2013
Date registered
1/08/2013
Date last updated
20/03/2017
Type of registration
Retrospectively registered
Titles & IDs
Public title
Using Positron Emission Tomography (PET) imaging to measure kidney function
Query!
Scientific title
In adults having Cr-51 EDTA glomerular filtration rate (GFR) estimation, what is the agreement with Ga-68 EDTA PET/CT?
Query!
Secondary ID [1]
282907
0
Nil Known
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Kidney function
289127
0
Query!
Condition category
Condition code
Renal and Urogenital
289467
289467
0
0
Query!
Kidney disease
Query!
Cancer
289468
289468
0
0
Query!
Any cancer
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
1. Ga-68 EDTA PET/CT scan (15-20 minute duration)
2. Small blood sample taken at several time points (2, 3, 4hrs) to count radioactivity which is used to determine renal function
Query!
Intervention code [1]
287143
0
Diagnosis / Prognosis
Query!
Comparator / control treatment
Conventional Cr-51 EDTA GFR plasma clearance. The same blood samples taken to count Ga-68 radioactivity, is also used to count Cr-51, so both can be directly compared.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
289569
0
Compare Ga-68 EDTA PET/CT calculated glomerular filtration rate (GFR) with results of Cr-51 EDTA. The GFR is calculated from the blood samples taken, and also from the PET scan.
Query!
Assessment method [1]
289569
0
Query!
Timepoint [1]
289569
0
Single time-point
Query!
Secondary outcome [1]
302749
0
Correlate assessment of differential or regional renal function with results of prior renal imaging. The contribution of each kidney to overall kidney function can be calculated from the PET scan. This will be compared to any prior tests that been performed for this purpose, usually a Tc-99m DMSA planar or SPECT/CT scan.
Query!
Assessment method [1]
302749
0
Query!
Timepoint [1]
302749
0
Single time-point
Query!
Eligibility
Key inclusion criteria
- Patient referred for Cr-51 EDTA study at our institution
- Age >= 18 years
- Written informed consent has been provided. One of the investigators will personally meet each candidate to explain the study and obtain written informed consent.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Participant is not able to tolerate supine position on PET/CT bed for the duration of the PET/CT acquisitions, is not cooperative, or needs continuous nursing (e.g. patient from Intensive Care Unit).
- Pregnancy
- Breast-feeding
Query!
Study design
Purpose of the study
Diagnosis
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
1/05/2012
Query!
Actual
1/06/2012
Query!
Date of last participant enrolment
Anticipated
31/12/2013
Query!
Actual
25/10/2013
Query!
Date of last data collection
Anticipated
Query!
Actual
25/10/2013
Query!
Sample size
Target
40
Query!
Accrual to date
Query!
Final
40
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
982
0
Peter MacCallum Cancer Institute - East Melbourne
Query!
Funding & Sponsors
Funding source category [1]
287273
0
Self funded/Unfunded
Query!
Name [1]
287273
0
Physician Sponsored
Query!
Address [1]
287273
0
Peter MacCallum Cancer Institute
St Andrews Place
East Melbourne VIC 3002
Query!
Country [1]
287273
0
Australia
Query!
Primary sponsor type
Individual
Query!
Name
Dr Michael Hofman
Query!
Address
Peter MacCallum Cancer Centre
St Andrews Place
East Melbourne VIC 3002
Query!
Country
Australia
Query!
Secondary sponsor category [1]
286026
0
Hospital
Query!
Name [1]
286026
0
Peter MacCallum Cancer Centre
Query!
Address [1]
286026
0
St Andrews Place
East Melbourne VIC 3002
Query!
Country [1]
286026
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
289253
0
Peter MacCallum Cancer Centre Ethics Committee
Query!
Ethics committee address [1]
289253
0
Ethics Committee Secretariat Peter MacCallum Cancer Centre Level 4, 10 St Andrews Place East Melbourne, VIC 3002
Query!
Ethics committee country [1]
289253
0
Australia
Query!
Date submitted for ethics approval [1]
289253
0
Query!
Approval date [1]
289253
0
04/04/2012
Query!
Ethics approval number [1]
289253
0
12/07
Query!
Summary
Brief summary
The study is comparing two different techniques to assess kidney function in patients referred to the Peter MacCallum Cancer Institute. Who is it for? You may be eligible to join this study if you are aged 18 years or above and have been referred to the Peter MacCallum Cancer Institute for assessment of kidney function. Trial Details. The determination of kidney function is utilised for a wide range of clinical decision making. At Peter MacCallum Cancer Centre, common clinical indications include dose adjustment for renally excreted chemotherapy agents (eg. carboplatin), determination of overall and split renal function prior to abdominal radiotherapy and monitoring of renal function during radionuclide therapy. Radionuclide techniques such as 51Cr-ethylenediaminetetraacetic acid (EDTA) blood clearance counting is a well-established method for estimation of GFR but requires blood samples from the patient at multiple time points and requires a well counter to accurately measure radioactivity at each time point which is not available in many nuclear medicine facilities. Positron emission tomography (PET) offers several advantages for imaging the kidneys over the conventional nuclear medicine technique. It has an order of magnitude higher sensitivity for radiotracer detection, enables dynamic tomographic (three dimensional) imaging, incorporates scatter and attenuation correction enabling accurate quantification of regional uptake and has superior spatial and temporal resolution. EDTA can be labelled with 68Ga, a positron emitting isotope which can be imaged on a PET/CT scanner. 68Ga EDTA PET/CT offers a non-invasive imaging-based alternative to 51Cr EDTA for GFR estimation. 68Ga EDTA PET/CT also has the ability to assess both overall and differential or regional renal function in a single study. Currently, many patients undergo both a 51Cr EDTA and a 99mTc-DMSA or 99mTc-DTPA to calculate overall and regional function, respectively. Although 68Ga EDTA standalone PET has been performed, there is limited experience and no data on its use in the PET/CT era or utility in comparison to 51Cr EDTA for GFR estimation. There are also no published reports, to our knowledge, using 68Ga EDTA to assess regional renal function. All participants in this study will undergo two different techniques to evaluate kidney function. This involves having an injection into a vein of a small of dose of two radioactive substances (68Ga and 51Cr-EDTA). A 20 minute PET scan is then performed looking at your kidneys. A small amount of blood is taken at 2, 3 and 4 hours.
Query!
Trial website
Query!
Trial related presentations / publications
1. Hofman M, Binns D, Johnston V, Siva S, Thompson M, Eu P, Collins M, Hicks RJ. 68Ga-EDTA PET/CT imaging and plasma clearance for glomerular filtration rate quantification: comparison to conventional 51Cr-EDTA. J Nucl Med. 2015 Mar;56(3):405-9. doi: 10.2967/jnumed.114.147843. PubMed PMID: 25678493. 2. Hofman MS, Hicks RJ. Gallium-68 EDTA PET/CT for Renal Imaging. Semin Nucl Med. 2016 Sep;46(5):448-61. doi: 10.1053/j.semnuclmed.2016.04.002. Review. PubMed PMID: 27553470.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
39990
0
Dr Michael Hofman
Query!
Address
39990
0
Peter MacCallum Cancer Centre
St Andrews Place
East Melbourne VIC 3002
Query!
Country
39990
0
Australia
Query!
Phone
39990
0
613 9656 1852
Query!
Fax
39990
0
Query!
Email
39990
0
[email protected]
Query!
Contact person for public queries
Name
39991
0
Michael Hofman
Query!
Address
39991
0
Peter MacCallum Cancer Centre
St Andrews Place
East Melbourne VIC 3002
Query!
Country
39991
0
Australia
Query!
Phone
39991
0
613 9656 1852
Query!
Fax
39991
0
Query!
Email
39991
0
[email protected]
Query!
Contact person for scientific queries
Name
39992
0
Michael Hofman
Query!
Address
39992
0
Peter MacCallum Cancer Centre
St Andrews Place
East Melbourne VIC 3002
Query!
Country
39992
0
Australia
Query!
Phone
39992
0
613 9656 1852
Query!
Fax
39992
0
Query!
Email
39992
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
Source
Title
Year of Publication
DOI
Embase
68Ga-EDTA PET/CT imaging and plasma clearance for glomerular filtration rate quantification: Comparison to conventional 51Cr-EDTA.
2015
https://dx.doi.org/10.2967/jnumed.114.147843
N.B. These documents automatically identified may not have been verified by the study sponsor.
Download to PDF